How Recent ADCs Developments Have Shifted Breast Cancer Care in Clinical Practice

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how recent advances in antibody-drug conjugates (ADCs) have reshaped clinical management across breast cancer subtypes. Iyengar highlights the rapid expansion of ADC indications and their increasing use in metastatic settings, particularly in heavily pretreated populations. Natsuhara emphasizes how clinicians are now integrating these agents more dynamically into treatment algorithms as real-world experience continues to grow.